Novartis AG Starts Supplying Meningitis B Vaccine To Princeton University

Published: Dec 09, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Swiss drugmaker Novartis said on Monday it had started supplying its meningitis B vaccine to Princeton University in an effort to stop an outbreak of meningitis on the Ivy League campus. Although the vaccine, called Bexsero, is not yet approved in the United States, the U.S. Food and Drug Administration has given the green light to its use at Princeton following an Investigational New Drug application from the Centers for Disease Control and Prevention (CDC). Eight students at the university have been diagnosed with the serogroup B strain of meningitis, a potentially fatal infection that causes swelling of the brain and spinal cord and can kill within 24 hours.

Help employers find you! Check out all the jobs and post your resume.

Back to news